Standard Biotools INC Form 4 insider transactions

Standard BioTools CEO Michael Egholm disposed of 54,919 shares of common stock to cover tax obligations from RSU vesting.

Standard BioTools SVP & Chief Business Officer Sean Mackay reported a disposition of 19,661 common shares for tax withholding purposes.

Standard BioTools CFO Hanjoon Alex Kim reported a disposition of 12,739 common shares to cover tax obligations from RSU vesting.

Investment funds associated with Eli Casdin increased their beneficial ownership in Standard BioTools Inc. through recent common stock purchases.

Standard BioTools Inc. Chief Financial Officer Hanjoon Alex Kim was granted 1.5 million Restricted Stock Units, aligning executive incentives with long-term company performance.

Standard BioTools Inc. President & CEO Michael Egholm was granted 3,000,000 Restricted Stock Units, vesting over four years.

Standard BioTools Director Troy Cox filed an amended Form 4 to correct the reported number of beneficially owned common stock shares to 319,322.

Standard BioTools Inc. Director Troy Cox has reported the acquisition of 94,592 Restricted Stock Units and 125,660 stock options, reflecting a significant equity grant as part of his compensation.

Standard BioTools Inc. Director Fenel M. Eloi was granted 94,592 Restricted Stock Units and 125,660 stock options, aligning his interests with shareholders.

Standard BioTools Inc. Director Thomas D. Carey was granted 94,592 Restricted Stock Units and 188,490 stock options on June 20, 2025, significantly increasing his beneficial ownership in the company.

Eli Casdin, a Director and 10% owner of Standard BioTools Inc., has reported the acquisition of 94,592 Restricted Stock Units and 125,660 stock options, increasing his direct and indirect beneficial ownership.

Standard BioTools Inc. Director Kathy L. Hibbs was granted 94,592 Restricted Stock Units and options to purchase 125,660 shares of common stock, aligning her interests with shareholders.

Standard BioTools Inc. Director Frank Witney has reported the acquisition of 94,592 Restricted Stock Units and 125,660 stock options, reflecting new equity compensation.

Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc., disposed of 23,919 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Michael Egholm, President & CEO and Director of STANDARD BIOTOOLS INC., disposed of 9,906 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Standard BioTools Inc.'s Chief Financial Officer, Hanjoon Alex Kim, reported the disposition of 2,583 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Standard BioTools Inc.'s Chief Financial Officer, Hanjoon Alex Kim, sold 1,428 shares of common stock for approximately $0.941 per share to satisfy tax obligations arising from the vesting of restricted stock units.

Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc., sold 13,217 shares of common stock to satisfy tax liabilities related to the vesting of restricted stock units.

Standard BioTools Inc.'s President and CEO, Michael Egholm, sold 5,473 shares of common stock on May 23, 2025, at a weighted average price of $0.941 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

Standard BioTools Inc.'s Chief Financial Officer, Hanjoon Alex Kim, sold 1,355 shares of common stock for approximately $1.002 per share to satisfy tax liabilities arising from the vesting of restricted stock units.

STANDARD BIOTOOLS INC. President and CEO Michael Egholm sold 5,116 shares of common stock for $1.002 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc., sold a total of 25,374 shares of common stock over two days in May 2025 to satisfy tax obligations related to the vesting of restricted stock units.

Michael Egholm, President & CEO of Standard BioTools Inc., reports disposition of shares to cover tax obligations arising from vesting of restricted stock units.

Hanjoon Alex Kim, CFO of Standard BioTools Inc., sold shares to cover tax obligations arising from the vesting of restricted stock units.

Michael Egholm, President & CEO of Standard BioTools Inc., reports the vesting of restricted stock units and subsequent tax withholding.

Hanjoon Alex Kim, CFO of Standard Biotools Inc., reports the vesting of restricted stock units and subsequent stock transactions to cover tax obligations.

Hanjoon Alex Kim, CFO of Standard Biotools, reports acquisition of shares and options in the company.

Sean Mackay, SVP & Chief Business Officer of Standard Biotools Inc., reports acquisition of restricted stock units and stock options.

Michael Egholm, President & CEO of Standard BioTools Inc., reports acquisition of shares and stock options.

Casdin Partners and related entities report acquiring and disposing of shares in Standard BioTools, along with grants of Restricted Stock Units (RSUs) to Eli Casdin.